

# ANNUAL REPORT 2025



Alliance Against Leprosy  
INSTITUTE

## INFO SHEET

Aliance Against Leprosy Institute

@aliancacontrahansenise

Annual Activity Report 2025

Drafted by: Nicole Morihama

Images: AAL Collection

Layout and drafting: Nicole Morihama

# Contents

**2** INFO SHEET

**4** MESSAGE FROM THE PRESIDENT

**5** MESSAGE FROM THE EXECUTIVE DIRECTOR

**7** ABOUT THE INSTITUTE

**8** OUR HISTORY

**9** OUR ORGANISATIONAL PRINCIPLES

**10** OUR TEAM

**11** KEY ACHIEVEMENTS

**12** IMPACT OF ACHIEVEMENTS

**13** PROGRAMME HIGHLIGHTS

**23** WHO WE SERVE

**25** THE SCALE OF OUR IMPACT

**29** OUR CONTRIBUTION

**30** GOVERNANCE AND INTEGRITY

**31** 2025 HIGHLIGHTS

**33** OUR ALLIES

**34** OUR TRANSPARENCY

**36** OUTLOOK FOR 2026

# Message from the President

The year 2025 marks a milestone in the trajectory of the Alliance Against Leprosy Institute. Beyond the expansion of results, we have consolidated an operating model oriented towards the structural transformation of the leprosy care pathway, both in Brazil and in international contexts.

Throughout this period, we strengthened institutional governance, refined our transparency mechanisms, and advanced the consolidation of strategic partnerships with public, private, and multilateral actors. This reflects an ongoing commitment to excellence, accountability, and sustainable impact.

The results presented in this report demonstrate not only the expansion of our actions, but above all the consistency of a qualified, evidence-based technical approach centred on persons affected by leprosy.



**Mr. Bernard de Laguiche**  
President of the AAL Deliberative Council

We remain firmly convinced that addressing leprosy demands more than isolated interventions – it requires systemic vision, continuous professional development for health workers, and the integration of care, science, and education.

The AAL Institute remains committed to this path, actively contributing to the development of lasting solutions and to the reduction of leprosy-related disabilities.

Enjoy the reading!

# Message from the Executive Director

In 2025, the Alliance Against Leprosy Institute reaffirmed its essence: to act with technical depth, human commitment, and a vision for the future.

Every figure presented in this report carries a story. Stories of people whose lives were transformed through access to rehabilitation, qualified care, and information. Stories of health professionals who, once trained, go on to multiply knowledge and expand impact across their territories.

We believe that leprosy is not merely a clinical issue — it is a social, structural, and historical challenge. This is why our work integrates science, education, and care in an indissociable way.

This year, we advanced in the training of health professionals, expanded access to assistive technologies, and strengthened our institutional presence in strategic national and international spaces, contributing to technical debate and to the development of public policies.



None of this would have been possible without the trust of our partners, the commitment of our team, and above all the strength of persons affected by leprosy, who inspire us every day.

We move forward with the conviction that it is possible to transform realities — with science, with care, and with responsibility.

**Dr. Laila de Laguiche**  
Executive Director — AAL

# Purpose of this Document

This Annual Report aims to present, in a systematic, verifiable, and internationally aligned manner, the performance of the Alliance Against Leprosy Institute (AAL) during the 2025 fiscal year.

The document was structured based on the IRIS+ methodological framework, encompassing the dimensions of What, Who, How Much, Contribution, and Risk, in order to ensure consistency in the collection, organisation, and analysis of the data presented.

Through this report, AAL seeks to transparently communicate the outputs, outcomes, and scale of the interventions carried out; to demonstrate the Institute's contribution to strengthening the leprosy care pathway – particularly with regard to professional training and disability prevention; and to provide comparable, auditable indicators for institutional stakeholders, strategic partners, and international organisations. Additionally, the document supports evaluation processes, decision-making, and efficient resource allocation, while reinforcing governance practices, risk management, and institutional accountability.

The data presented were consolidated from operational records, technical reports, and internal monitoring systems, in accordance with criteria of traceability, consistency, and information integrity – in line with the Institute's commitment to impact-oriented management, transparency, and the adoption of internationally recognised standards for results reporting.

# About the Institute

The Alliance Against Leprosy Institute (AAL) is a non-profit civil society organisation dedicated exclusively to the fight against leprosy.


Headquartered in Curitiba, the Institute operates in Brazil and internationally, promoting health, dignity, and quality of life for persons affected by leprosy through integrated actions in prevention, diagnosis, treatment, rehabilitation, and social inclusion.

AAL's work is structured around **three complementary pillars:**

- **Science** – production and dissemination of technical and scientific knowledge
- **Education** – training of health professionals and strengthening of care networks
- **Care** – implementation of practical solutions for disability prevention and rehabilitation

The Institute is also committed to reducing the stigma and discrimination associated with the disease, promoting qualified information and raising social awareness.

Its work is carried out in collaboration with public institutions, referral centres, civil society organisations, and international bodies, contributing to the strengthening of the leprosy care continuum.



# Our History

Since its founding in 2018, the AAL Institute has built a trajectory marked by innovation, technical commitment, and progressive impact expansion.


The Institute was created with the purpose of integrating science and care in a field historically characterised by structural gaps – particularly in rehabilitation and disability prevention.

Over the years, it has developed proprietary methodologies, built strategic programmes, and expanded its territorial reach to different regions of Brazil, while growing its international presence.

Key milestones along this journey include:

- Establishment of the TECHansen, FeetHansen, and DOCHansen programmes
- Implementation of specialised rehabilitation workshops
- Expansion of health professional training at national scale
- Engagement in strategic spaces for technical and scientific discussion
- Consolidation of institutional partnerships with referral centres and international organisations

In 2025, the Institute reaches a new level of institutional maturity, with operations across multiple Brazilian states, a consolidated international presence, and growing recognition for the technical consistency of its actions.



**Impact  
and Scope**

# Organisational Principles

## **Mission**

To promote health, dignity, and quality of life for persons affected by leprosy, through integrated actions in science, education, and care.

## **Vision**

To be a national and international reference in the fight against leprosy, contributing to the reduction of disabilities and to the strengthening of the care continuum.

## **Values**

- Commitment to human dignity
- Technical excellence
- Ethics and transparency
- Impact-driven innovation
- Respect and active listening

## **Principles of Action**

- Centrality of persons affected by leprosy
- Scientific grounding and evidence-based decision-making
- Integration of care, education, and research
- Collaborative and inter-institutional engagement
- Sustainability and social responsibility

## **Institutional Structure and Governance**

The AAL Institute adopts a governance model grounded in transparency, accountability, and technical rigour.

Its structure comprises a Board of Directors, a Fiscal Council, a Scientific Committee, an Executive Directorate, and a technical and operational team.

The Institute's governance is guided by clear directives, with defined roles, structured decision-making processes, and robust oversight and monitoring mechanisms.

# Our Team

Active members in 2025:

## **Deliberative Council**

President: Bernard de Laguiche

Effective Councillor: Professor Dr. Aguinaldo Gonçalves

Effective Councillor: Professor Dr. Marcos da Cunha Lopes Virmond

Patient Representative: Francisca Barros da Silva – Dide

## **Executive Directorate**

Executive Director: Dr. Laila de Laguiche

Scientific Director: Dr. Marcelo Távora Mira

Technical Director: Dr. Susilene Maria Tonelli Nardi

## **Fiscal Council**

Angela do Rocio Kampa Matimoto Koide

Carolina Chaves Hauer

Feredico Nin Stern

## **Ombudsperson**

Ester Athanásio

## **Staff**

Nicole Morihama – COO - General Manager, AAL Institute; Public Relations

Amaralina Portilho – TECHansen Programme Monitor and Occupational Therapy student



2025



# KEY ACHIEVEMENTS



Alliance Against Leprosy  
INSTITUTE

# Impact of Achievements

The year 2025 was marked by **significant progress** across all of the Alliance Against Leprosy Institute's strategic fronts, consolidating its institutional presence, **expanding national and international partnerships**, launching new care and training initiatives, and earning recognition for its **excellence in management** and **social impact**. Below are the Institute's principal achievements of the year.



## Institutional expansion and recognition

- AAL ran a Social Advertising campaign in partnership with RPC, reaching more than 6 million people.



## New programmes and initiatives

- **Launch of DOCHansen Psychological Support**, providing free online psychological counselling to patients and their families.
- **Launch of the InformeHansen educational series**, produced in partnership with Mobius Life Science.
- **Hosting of Ágora 2025** — the AAL Allied Units Meeting, bringing together leaders from the country's main partner institutions.



## New partnerships and technical cooperation

- **Technical Cooperation Agreement with Hospital São Julião** (Campo Grande, MS) for the implementation of a specialised shoe workshop under the FeetHansen programme.
- **Partnerships** with Lojas Ciriana, Ótica Visorama, Grupo Madero, and Grupo Vonder for the donation of supplies to the TECHansen project.



## International engagement


- AAL was officially recognised as a Consultative Observer of the Community of Portuguese Language Countries (CPLP).
- AAL became an official member of GlobalSkin — The International Alliance of Dermatology Patient Organizations.
- The Institute participated in the 22nd International Leprosy Congress (ILC 2025), held in Bali, Indonesia.
- AAL was recognised as an Official Supporter of the International Leprosy Association (ILA) for the 2025–2026 biennium.
- The Institute hosted young volunteers from St. Thomas Aquinas Parish (California, USA) on a field mission in Pernambuco.
- Participation in the WHO Global Meeting on Skin-Related Neglected Tropical Diseases, held in Geneva.

# Programme Highlights

IRIS+ Framework — What Dimension: What we do

## A Focus on Integral Care

Leprosy leaves marks that go far beyond clinical treatment — physical, functional, and emotional. It is within this gap that the AAL Institute's core programmes operate, forming a network of care that accompanies the person across different dimensions of their life.



**TECHansen** provides free assistive technology to persons with physical disabilities caused by leprosy, promoting functional rehabilitation and daily autonomy.

**FeetHansen** focuses specifically on the feet — one of the body regions most vulnerable to leprosy — providing adapted insoles and custom-made footwear that protect against the worsening of lesions and enable a fuller life.

**DOCHansen** Psychological Support addresses emotional suffering that is frequently overlooked: through free online sessions, it provides support to patients and family members confronting the stigma and isolation that still surround the disease.

Together, these initiatives embody the AAL Institute's commitment to truly integral care — treating the body, protecting mobility, and caring for the mental health of those living with the consequences of leprosy.

In 2025, **TECHansen advanced both in its reach and in the dissemination** of knowledge. The programme deepened its integration with partner health units across different states through technical training for prescribing professionals – ensuring that knowledge about assistive technology is transferred locally and that more patients can receive quality, continuous care.

Throughout the year, the initiative consolidated its role as a benchmark in the field of rehabilitation and disability prevention in leprosy in Brazil, demonstrating that the combination of technological innovation, professional training, and direct patient care is an effective pathway to transforming the reality of those living with the sequelae of the disease.

### TECHansen 2025

Institute Alliance Against Leprosy (AAL) - Impact Indicators

**313**

People affected by leprosy benefited

**2,519**

A.T. Devices donated

**70**

Engaged health professionals

**10**

Partner donor organizations and companies of supplies

**24**


Brazilian states served

#### A.T. DEVICES PER PATIENT

**8,0**

average devices donated per leprosy-affected individual served  
(2,519 devices ÷ 313 patients)

Cumulative evolution 2021-2025  
A.T. Items donated



\* cumulative from 2021

### TECHANSEN — ANNUAL REPORT 2025

Annual growth indicators  
Cumulative comparison 2024 → 2025

Contemplated patients

**1,045**

↑ +43%

A.T. Items donated

**8.961**

↑ +39%

Prescribing professionals

**274**

↑ +34%

States served

**24**

= stable

# Devices that transform *lives*

Concept:

**Dr. Susilene Maria Tonelli Nardi**

Implementation:

**Alliance Against Leprosy Institute**

Funding:

**CIOMAL - International Order of Malta against Leprosy**



In 2025, DOCHansen experienced a year of profound transformation — marked not only by the growth of the tele-interconsultation platform, but by the launch of an entirely new dimension: mental health care for those living with leprosy.

The launch of **DOCHansen Psychological Support** responded to a historically invisible need: the stigma of leprosy imposes isolation, shame, and suffering that persist long after clinical cure — and that no antibiotic can treat.


DOCHansen — 2025 Annual Report

Annual Growth Indicators

Alliance Against Leprosy Institute (AAL)



Trained professionals — cumulative evolution



DOCHansen Psychological Support — first year



Brazil

Angola

Guinea-Bissau

Mozambique

USA

\* cumulative since 2023

In 2025, DOCHansen extended beyond Brazil's borders to become a truly international platform. The programme provides support to patients and health professionals in five countries: Brazil, the United States, Angola, Guinea-Bissau, and Mozambique — connecting realities as distinct as a primary health unit in the Brazilian interior and the African diaspora in the United States.

The platform fulfils a particularly critical role: **bringing qualified leprosy knowledge to contexts where it rarely reaches.**



**he specialist who  
reaches the patient**



Aliança Contra Hanseníase  
INSTITUTO



# FeetHansen

SAPATARIAS

In 2025, FeetHansen experienced its year of **greatest expansion** since the programme's creation. The production of handcrafted custom footwear – the heart of the initiative – grew expressively, driven by the establishment of three new AAL Shoe Workshops, which doubled the national network: from three to six units operating across Brazil.

## FeetHansen 2025

Alliance Against Leprosy Institute (AAL) · Prevention of Impairments · Production and Impact Indicators

**613**

People affected by leprosy benefiting

**722**

Custom-made insoles

**215**

Handcrafted custom shoes

**142**

Footwear modifications

**19**

Active health professionals

### ORTHOTICS PRODUCTION – ITEMS BY CATEGORY

Insoles		722
Custom shoes		215
Footwear modifications		142

TOTAL ITEMS PRODUCED

**in 2025: 1079**



*"I received the insoles and they adjusted my footwear just the way I needed, because I have many wounds on my feet and have already had part of my left foot amputated. The difference was enormous. Today I can walk with more confidence [...] and I am very happy!"*  
**J.B.d.S., 58 years old.**




**Feet**HANSEN

SAPATARIAS

5

shoe workshops in operation,  
established since 2021



1

Alta Floresta (MT)\*

2

Tangará da Serra (MT)\*

3

Hospital Dermatologia Sanitária do PR - HDSPR

4

Instituto Lauro de Souza Lima - ILSL

5

Hospital São Julião - HSJ

\* Established by AAL, operating independently since 2024

\*\* cumulative since 2021

2025



Feet HANSEN

613  
patients  
served

Coverage across  
1,139 cities

- Mato Grosso: 16 municipalities
- São Paulo (SP): 645 municipalities
- Paraná (PR): 399 municipalities
- Mato Grosso do Sul (MS): 79 municipalities

937  
orthoses  
donated

722 insoles produced  
215 handcrafted custom shoes

GULITI AUGUSTO SILVA  
Physiotherapist, Orthotist and Prosthetist  
ILSL





# Offering dignity and mobility

The installation of an AAL Shoe Workshop at Hospital São Julião (HSJ) in Campo Grande, Mato Grosso do Sul, represents one of the most significant milestones for FeetHansen in 2025.


HSJ is one of Brazil's most established institutions in leprosy treatment – a historic reference for the entire Central-West region and for patients from neighbouring states. Bringing a specialised shoe workshop into this unit means integrating foot care directly into the care flow of one of the country's most experienced institutions in leprosy management.



The partnership was formalised in January 2025 and included the training of the local physiotherapy team in the production of personalised orthopaedic insoles and footwear adaptations – transferring specialised technical knowledge to professionals who already work directly with persons affected by leprosy.

**Team of physiotherapists, occupational therapists, and nurses from HSJ.**





**“with the assistive technology donations** I received from the Institute [AAL], today I can do practically everything I want, without depending on anyone. I feel much safer.”  
**L.M.S, 64 years old.**

Testimonial from a patient supported by the TECHansen programme





## Who We Serve

**Brazil is the 2nd country with the highest number of cases in the world**

**More than 20,000 new cases per year in the country**

Brazil recorded a leprosy detection rate of approximately 10 cases per 100,000 inhabitants in 2024 — ten times above the WHO elimination target of fewer than 1 case per 10,000 inhabitants — confirming that the disease remains a serious public health challenge in the country.

**Most vulnerable profile:** male, average monthly income of up to R\$170 per person, low educational attainment, resident in overcrowded housing, Black or mixed-race.

*Source: FioCruz*

**We work for those who cannot wait.**

# Who We Serve

## IRIS+ Framework — Who Dimension


In 2025, the Alliance Against Leprosy Institute consolidated something few health institutes can claim: an active presence in 24 of Brazil's 26 states, plus the Federal District. This vast capillarity follows the logic of the disease — and leprosy, in Brazil, does not respect administrative boundaries.

In 2025, WHO reports indicated that 172,671 new cases were recorded worldwide, with 22,129 in Brazil — representing 12.8% of the global total, maintaining the country in second position, behind only India.

The distribution of cases consistently points in the same direction: regions with limited access to specialised health services, greater socioeconomic vulnerability, and historically lower levels of public policy attention.

It is to these regions that the AAL Institute directs its priority efforts. In the North and Northeast — where the disease's detection rates are highest in the country — the Institute intensified health professional training and TECHansen expansion in 2025, through a network now comprising 274 registered professionals. In the Central-West, the installation of an AAL Shoe Workshop at Hospital São Julião in Mato Grosso do Sul marked the Institute's arrival at one of Brazil's most historically significant leprosy referral hospitals.

The territorial expansion of 2025 extended beyond national borders. Through the DOCHansen platform and partnerships with national disease control coordinators, the Institute consolidated its presence in Angola, Guinea-Bissau, and Mozambique — Portuguese-speaking countries where leprosy remains a significant public health challenge.




# The Scale of Our Impact

## IRIS+ Framework — How Much Dimension

Under this methodology, **SCALE** refers to how many people were reached by the work.

**DEPTH** measures the degree of change experienced by those people — that is, the intensity and quality of the impact generated.

**DURATION** indicates how long this change persists in the lives of beneficiaries.



Together, these three dimensions answer the central question of the IRIS+ framework:  
**how much impact was genuinely produced?**

In 2025, the AAL Institute's figures tell a story of consistent growth, expanded reach, and qualitative deepening of its actions. This is not merely about more patients or more trained professionals — it is about a denser, better distributed, and more diverse network of care.



**consistent growth**



**expanding reach and**



**qualitative deepening of actions**

### Key Indicators 2025

Alliance Against Leprosy Institute (AAL) · IRIS+ Framework

**941**

Affected persons treated directly

**4,705**

Indirect beneficiaries

**7,546,400**

Total persons impacted

**24 states + 3 countries**

Geographic reach

**568 h**

Training hours

**505**

Psychological counseling sessions

**3,456**

Rehabilitation tools donated

**2,439**

Trained health professionals

**722**

Insoles produced

**215**

Custom artisanal shoes

**142**

Footwear adaptations

**55**

Volunteers involved

# The Scale of Our Impact


# Our voice and reach

In 2025, the Alliance Against Leprosy Institute went beyond direct care for persons affected by leprosy – **reaching the topic to more than 7.5 million people**. This reach was made possible through a structured communication strategy, with particular emphasis on social advertising, which alone **impacted 6.6 million people** – transforming visibility into collective awareness about a disease still marked by stigma and silence. Added to this were 850,000 people reached through television and press coverage, and nearly 100,000 through digital platforms. Every person reached represents an opportunity to break the cycle of misinformation that delays diagnoses and perpetuates disabilities – and AAL, in 2025, occupied this space with intention and at scale.



Click here to [watch the campaign video](#).

# 7.5 million people reached with quality information



# The Scale of Our Impact

## 2025 Indicators Panel

The 2025 indicators reflect a year of expressive growth and qualitative deepening of the Alliance Against Leprosy Institute's actions. With 941 persons affected by leprosy directly served and 2,439 health professionals trained, the Institute consolidated its dual impact strategy: direct patient care and the strengthening of local care networks – complementary dimensions that expand the reach and sustainability of the results generated.

At the operational level, the figures reflect the maturity and diversity of ongoing actions. These include 3,598 rehabilitation and assistive technology items donated through TECHansen; 722 orthopaedic insoles and 215 handcrafted custom shoes produced through FeetHansen; and 505 psychological consultations delivered in the first full year of DOCHansen Psychological Support. Added to this are 568 training hours delivered, 55 volunteers engaged, and 4,705 indirect beneficiaries – a set of outputs that demonstrates, with objectivity, the scale and depth of the impact produced by the Institute in 2025.

**expressive growth and  
qualitative deepening  
of actions**

**941**

Affected persons treated directly

TECHansen + FeetHansen

**2.439**

Trained health professionals

DOCHansen + Shoe Factories

**3.598**

Rehabilitation tools and A.T. donated

TECHansen

**722**

Produced orthopedic insoles

FeetHansen

**215**

Custom-made artisanal footwear

FeetHansen

**505**

Conducted psychological sessions

DOCHansen · 1st year

**568h**

Conducted training hours

All actions

**55**

Volunteers involved in the projects

2025

**4.705**

Indirect beneficiaries

All actions

# The Scale of Our Cumulative Impact

## Indicators Panel — cumulative historical data 2021–2025

The figures below represent the cumulative total of the AAL Institute's entire trajectory since the beginning of structured actions in 2021. They are a portrait of seven years of construction, partnership, and presence alongside persons affected by leprosy in Brazil and around the world.



*Methodological note: the 'Cumulative 2024' values represent historical totals recorded up to 31 December 2024. The 'Cumulative 2025' values add the historical total to the deliveries of the 2025 fiscal year. The percentage variation reflects the growth of the cumulative stock.*



*"I used to look at my foot and could not believe it was mine. The wound would not close; I could not put on a shoe. I stopped working. I stayed at home, too ashamed to go out. When I received the footwear from the Institute, within the first week I could already walk without pain. It was the first time in two years that I had walked to the bakery on my own."*

*S.R, 47 years old. São Paulo.*

## IRIS+ Framework — Contribution Dimension

### The role of the AAL Institute in generating results

The Contribution dimension seeks to establish the extent to which the observed results can be attributed to the direct work of the Alliance Against Leprosy Institute. To understand this, it is necessary to consider the systemic context of leprosy in Brazil: a landscape marked by inequalities in access, persistent care gaps, and insufficient provision of specialised rehabilitation — particularly in the regions where the disease is most prevalent.

In this context, AAL acts not merely as a service provider, but as a catalyst for structural change, expanding access to services and solutions that, in much of the territory, would simply not be available without its intervention.

AAL's contribution is defined above all by its **additionality** — by the provision of solutions that would not be fully deliverable by the public system or by other organisations at the same level of scale, quality, and specialisation.

TECHansen provides specialised assistive technologies — such as thermal gloves and adapted utensils — still largely absent from the public health network. FeetHansen produces and adapts orthopaedic devices with a direct focus on disability prevention, reaching regions without structured workshops for this purpose. DOCHansen offers continuous, specialised psychological support to patients and families, in a regular model that does not exist in most leprosy referral services in the country.

Together, these initiatives address critical gaps in the care system, reducing the risk of clinical deterioration and promoting functional autonomy for those who need it most.

AAL's impact extends beyond direct service delivery. By training health professionals, establishing specialised shoe workshops, and transferring technical knowledge to local teams, the Institute generates a **multiplier effect**: every trained professional expands the reach of care in their own territory, autonomously and sustainably.

Added to this is the systematic **reduction of barriers** — geographical, economic, and social — that have historically kept persons affected by leprosy from accessing integral care. Presence in 24 states and 3 countries.

## Fully free services.

Psychosocial support integrated into the care flow.

Finally, AAL serves as a **bridge between science, innovation, and care practice**, strengthening public policies, participating in strategic decision-making spaces, and building partnerships with referral hospitals, universities, and international organisations.

In many of the cases served in 2025, the outcomes — mobility restored, disability prevented, autonomy re-established — would not have occurred without the Institute's presence. This is, in essence, the measure of AAL's contribution: **\*\*not merely being part of the solution, but being, in many contexts, the only solution available.**

**AL's contribution is defined by what it adds to the system: specialised solutions delivered with the scale and quality that the public sector, alone, cannot yet guarantee to persons affected by leprosy.**

## IRIS+ Framework — Risk Dimension: Risk management and impact safeguards

Every impact-driven organisation must be honest about its limitations and vulnerabilities. The Alliance Against Leprosy Institute acknowledges the risks inherent in its operating model and adopts an active stance of identification, monitoring, and mitigation — understanding risk management not as bureaucracy, but as an integral part of its commitment to the seriousness and sustainability of its work.

As a mitigation strategy, AAL continuously invests in the diversification of institutional partnerships, in building ties with international organisations, and in strengthening its technical credibility as a means of broadening its support base.

**Impact risks** relate to the durability and depth of the changes generated. There is a risk that beneficiaries may not sustain functional gains after the conclusion of follow-up, or that the absence of longitudinal data may limit the measurement of long-term outcomes — particularly in disability prevention. To reduce this exposure, the Institute adopts standardised technical protocols, promotes the training of local teams as a continuity strategy, and is advancing the development of more robust monitoring systems.

**Operational risks** include dependence on volunteers and reduced teams for the execution of technically complex actions. AAL mitigates this risk through the formalisation of partnerships with health institutions, the systematic transfer of knowledge, and the structuring of local networks capable of operating with increasing autonomy.

Awareness of these risks does not weaken the Institute — on the contrary, it reinforces its commitment to responsible, transparent management oriented towards the generation of real and lasting impact.

The AAL Institute maintains structured institutional governance protocols, with clearly defined roles, documented decision-making processes, and robust oversight and monitoring mechanisms.

As evidence of this commitment, all of AAL's activities for the 2025 fiscal year were submitted to an independent audit conducted by Mazars — a global audit and consulting firm — and were approved without reservation. This result reinforces the reliability of the information presented in this report and the Institute's commitment to transparency before its partners, funders, and society.

**Governance of  
excellence and  
institutional  
integrity**

**forv/s  
mazars**

# 2025 Highlights


In 2025, the Alliance Against Leprosy Institute advanced across all fronts of its work, consolidating its position as a national and international reference in the fight against leprosy.

**Institutionally**, the year was marked by historic achievements: the formalisation of a technical cooperation agreement with Hospital São Julião (MS); accreditation with the International Leprosy Association (ILA); the attainment of Consultative Observer status at the CPLP; and membership in GlobalSkin. The Institute was also selected by GRPCOM for the Adote uma Causa (Adopt a Cause) Project, and concluded the year with Ágora AAL 2025 — a face-to-face meeting in Campo Grande that brought together managers from the Institute's main partner referral units across Brazil.

**In direct care**, the highlight was the launch of DOCHansen Psychological Support — a pioneering initiative that began offering free online psychological counselling to patients and families anywhere in the country. The Institute also received a mission of seventeen international volunteers from St. Thomas Aquinas Parish (California, USA), who worked in the field in Pernambuco, visiting referral hospitals, distributing self-care kits, and producing awareness content.

**In education**, the Institute delivered in-person training in assistive technology for health professionals in Mato Grosso do Sul, Paraíba, and Rio Grande do Norte, training physicians, nurses, physiotherapists, and occupational therapists in physical disability prevention. In September, the InformeHansen educational series was launched — six institutional videos produced in partnership with Mobius Life Science — broadening health communication about leprosy to audiences beyond the medical sector.


**In science**, the Institute participated in the Second WHO Global Meeting on Skin-Related Neglected Tropical Diseases, in Geneva, and in the 22nd International Leprosy Congress (ILC 2025), in Bali. It analysed and published the WHO global epidemiological report — which recorded 22,129 new leprosy cases in Brazil in 2024 — and concluded the year with the launch of an open call for clinical case reports in partnership with the journal Hansenologia Internationalis, integrating science, clinical practice, and the third sector in national scientific production.



**ÁGORA AAL 2025**

Encontro das Unidades de Referência em Hanseníase Aliadas AAL

23 e 24 de outubro  
Campo Grande / MS



**Cadastro de Profissionais de Saúde com atuação em Hanseníase**

Aliança Contra Hanseníase INSTITUTO

2024



# Our Allies

## Parceiros

info Hansen



MADERO



ÓTICAS VISORAMA



programa impulso



## Assessoria Pro Bono

MAZUTTI RIBAS STERN  
SOCIEDADE DE ADVOGADOS



Google for Nonprofits



## Cooperações



## Parceria internacional

Companhia Internacional da Ordem de Malta contra a Hanseníase  
(CIOMAL, na sigla em francês)



ORDEM DE MALTA  
COMBATE À HANSENÍASE

FUNDAÇÃO CIOMAL

Faça parte desta aliança

## Prestadores de serviços



mazars



# Transparency

---

## Governance to International Standards

The AAL Institute grounds its work **in solid principles of governance, integrity, and accountability**. Transparency is not merely a legal obligation – it is an ethical commitment to all persons affected by leprosy who depend on the effectiveness of AAL's actions, to the partners who trust the institution, and to the society that supports the cause.

In 2025, all accounts of the Alliance Against Leprosy Institute (AAL) were submitted to an **independent audit** conducted by Mazars, a global audit and consulting firm with a presence in more than 90 countries, recognised for its rigorous technical and ethical standards. The financial statements were approved without reservation, attesting to the regularity, legality, and fidelity of the organisation's accounting records.

This result reflects AAL's commitment to the **highest international governance standards** for third-sector organisations – from rigorous oversight of income and expenditure to the responsible management of resources entrusted by donors, partners, and volunteers.

The deficit recorded in the 2025 fiscal year reflects AAL's continued investment in the expansion of its actions and in the development of new projects aimed at disability prevention and integral care for persons affected by leprosy. It is important to note that, despite the accounting deficit, the organisation's cash flow remained positive throughout the year, sustained by accumulated account balances – the result of prudent and planned financial management in prior periods.

The Institute continuously monitors its financial health and adopts proactive planning measures to ensure long-term institutional sustainability.


The economic value of volunteer contributions demonstrates the strength of the network of collaborators who dedicate their time and expertise to the Institute's mission, and is recorded transparently in both income and expenditure, in accordance with good accounting practices for civil society organisations.

AAL's accountability reporting consolidates its credibility with national and international partners, reaffirming that resources received are managed with responsibility, rigour, and full commitment to the mission of eliminating leprosy as a public health problem in Brazil and around the world.

# Transparency

## Financial Statements 2025

Distribution of investments by programme



In our commitment to transparency and internationally recognised accountability, we undergo an annual external audit conducted by MAZARS, an internationally recognised firm operating in 90 countries.

[Click here to access the full 2025 Financial Audit Report](#)

**mazars**

## \*Strategic Horizon

2025 demonstrated that the Alliance Against Leprosy Institute's model works – and that there is much more to be done. The year 2026 will be an opportunity to consolidate what has been built and to advance with greater scale, more partnerships, and deeper impact.


**In programmes and initiatives**, AAL will continue to deepen the integration between TECHansen, FeetHansen, and DOCHansen, broadening the provision of integral care for persons affected by leprosy through the new SelfHansen initiative. New educational and awareness-raising efforts are planned in partnership with media and health organisations.

**In geographical expansion**, the Institute will advance the establishment of new AAL Shoe Workshops, prioritising regions with high detection rates and limited availability of specialised rehabilitation – particularly in Brazil's North and Northeast. The target is to expand the current network from five to seven operational units.

**In international expansion**, AAL will deepen its engagement in European and American countries, opening new avenues for multilateral partnerships.

**In new strategic partnerships**, the Institute will seek to expand its network of partner referral hospitals, strengthen ties with universities and research centres, and consolidate alliances with the private sector for the donation of supplies and co-funding of initiatives.

**In institutional strengthening**, AAL will invest in the professionalisation of its monitoring and evaluation processes, in expanding its technical team, and in the development of more robust impact management systems – ensuring that data presented in future reports are even more traceable and comparable.



**In resource mobilisation**, the Institute will advance the diversification of its funding base, reducing dependence on a small number of partners and expanding its presence among international foundations, multilateral organisations, and financing mechanisms for neglected tropical diseases.

The horizon of 2026 is clear: more people reached, with higher-quality care, in more territories – and an Institute increasingly solid in its capacity to sustain that impact over time.



# Alliance Against Leprosy

---

I N S T I T U T E



<https://www.aal.org.br>



[aal@aal.org.br](mailto:aal@aal.org.br)



+55 41 99247-8873



Rua Deputado Heitor Alencar Furtado, nº 3350  
sala 103, Condomínio Opus One Ecoville  
Bairro Campo Comprido  
CEP: 81200-528, Curitiba - PR.  
Brasil.